PENNY WATCH

[Pennybuster]

Amyris Inc $AMRS Lifted to “Buy” at Zacks Investment Research
Posted by Tony Sherman on May 17th, 2016 //

Amyris Inc logoZacks Investment Research upgraded shares of Amyris Inc (NASDAQ:AMRS) from a hold rating to a buy rating in a research report released on Thursday. Zacks Investment Research currently has $0.75 price objective on the stock.
According to Zacks, “Amyris INC is an integrated renewable products company applying industrial synthetic biology to genetically modify microorganisms to serve as living factories. Amyris designs these microorganisms to produce defined molecules for use as renewable chemicals and transportation fuels. The Company is engaged in the development of farmesene- a molecule, which serves as the base chemical building block for a wide range of renewable products to replace existing products that are derived from petroleum, plant or animal sources and that may be of lower quality or higher price. Amyris INC is headquartered in Emeryville, CA. “
Amyris (NASDAQ:AMRS) opened at 0.5903 on Thursday. The firm’s 50-day moving average is $1.00 and its 200 day moving average is $1.35. Amyris has a 52-week low of $0.56 and a 52-week high of $2.62. The company’s market cap is $121.86 million.


Amyris (NASDAQ:AMRS) last issued its quarterly earnings results on Tuesday, May 10th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by $0.04. The business earned $8.80 million during the quarter, compared to analysts’ expectations of $10.39 million. The company’s revenue was up 11.8% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.41) earnings per share. On average, equities research analysts predict that Amyris will post ($0.31) EPS for the current fiscal year.
Separately, Cowen and Company reissued a market perform rating and issued a $2.00 price target (down from $2.50) on shares of Amyris in a research note on Thursday, March 10th.
Several institutional investors have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. raised its position in Amyris by 302.3% in the first quarter. Goldman Sachs Group Inc. now owns 101,704 shares of the company’s stock valued at $113,000 after buying an additional 76,423 shares in the last quarter. Jacobs Levy Equity Management Inc. purchased a new position in Amyris during the first quarter valued at $269,000. Finally, Geode Capital Management LLC raised its position in Amyris by 11.6% in the first quarter. Geode Capital Management LLC now owns 298,669 shares of the company’s stock valued at $331,000 after buying an additional 30,958 shares in the last quarter.
Amyris, Inc is a renewable products company. The Company is focused on providing sustainable alternatives to a range of petroleum-sourced products used in consumer care, specialty chemical and transportation fuel markets around the world. The Company developed microbial engineering and screening technologies that modify the way microorganisms’ process sugars.



$AMRS Filing With Bill and Melinda Gates Foundation.


http://ih.advfn.com/p.php?pid=nmona&article=71476165

As previously reported, on April 8, 2016, Amyris, Inc. (the “ Company ”) and the Bill & Melinda Gates Foundation (the “ Gates Foundation ”) entered into (i) a Securities Purchase Agreement (the “ Purchase Agreement ”), pursuant to which the Company agreed to sell and issue 4,385,964 shares of its common stock (the “ Shares ”) to the Gates Foundation at a purchase price per share equal to $1.14 (the “ Gates Foundation Investment ”) and (ii) a Charitable Purposes Letter Agreement (the “ Letter Agreement ”), pursuant to which the Company agreed to use the proceeds from the Gates Foundation Investment to develop a yeast strain that produces artemisinic acid and/or amorphadiene at a low cost and to supply such artemisinic acid and amorphadiene to companies qualified to convert artemisinic acid and amorphadiene to artemisinin for inclusion in artemisinin combination therapies used to treat malaria. The entry into the Purchase Agreement and the Letter Agreement was previously reported in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 11, 2016, which is incorporated herein by reference.

On May 10, 2016, the Company and the Gates Foundation closed the Gates Foundation Investment, resulting in the issuance of 4,385,964 Shares to the Gates Foundation for proceeds to the Company of approximately $5.0 million.


https://biz.yahoo.com/e/160513/amrs8-k.html